2 results
Approved WMOCompleted
To study the potential renoprotective effects of supplementation of alkaline phosphatase in hospitalized patients with AKI
Approved WMORecruiting
To determine the immune-related progression free survival (irPFS) rate at 21 weeks and objective response rate (irORR) at 30 weeks in patients with pMMR CRC, dMMR mCRC, dMMR EC , dMMR SBC, dMMR SC treated with pembrolizumab combined with ataluren…